secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001193125-25-115482
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q1 Portfolio Receipts $839M (+17% YoY); raises FY2025 guidance
-----------------------------------------------------------------------------

- Royalty Receipts grew 12% to $788M; cystic fibrosis franchise, Trelegy, Xtandi drove growth.
- Raised FY2025 Portfolio Receipts guidance to $2,975M-$3,125M (prior $2,900M-$3,050M).
- Repurchased 23M shares for $723M under new $3B buyback program.
- Internalization of manager RP Management ($1.1B) vote May 12, closing expected Q2 2025.
- Biogen R&D funding for litifilimab (up to $250M); $50M upfront in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525115482/0001193125-25-115482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525115482/d938501d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-115482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer